Skip to content
Catalyst

pterostilbeneFinding

Pterostilbene decreases systolic blood pressure (setting unspecified)

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“There was a significant reduction versus placebo in SBP and DBP with high dose pterostilbene (see Figure 2).”
Quoted verbatim from Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.
This finding among the 88 findings on its endpoint

pterostilbene

Systolic blood pressure (setting unspecified)

lowers

Who
Adults with hypercholesterolemia; high-dose arm only (pterostilbene 125 mg twice daily) against matching placebo, 6-8 weeks
Dose studied
pterostilbene 125 mg orally twice daily

Moderate evidencePMID 25057276 · 2014

02 · The study

Study
RCT
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Evidence-based complementary and alternative medicine
What else it reported2 findings · 1 compound · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M71EJWYY4DWQZ45DAG0V8XG1